Gene therapy, stem cells, and other advances are changing the way complex diseases are treated. To capitalize, biopharma and biotech companies need to make strategic decisions about where to focus their efforts.
Stakeholder support is crucial for ensuring that African vaccine-manufacturing companies can produce sufficient supply for the continent.
Pharma has invested billions in cell and gene therapies. Gene editing is making a case for more of this funding, but companies need to understand what they’re investing in and why.
To become leaders in the field, biopharma companies must understand unmet needs and evolving standards of care and make greater use of real-world evidence.
The finances of the US health system are weak. If systemic issues are not resolved, the situation will worsen, with detrimental consequences for patient care and care equity.
A confluence of factors means the time-tested approaches to cost control won’t work. Insurers need to rethink how they achieve more with less while maintaining a strong customer focus and employee value proposition.
A new regulation makes detailed pricing data widely available for the first time. Providers and insurers need to prepare now for a changed competitive playing field.
An employee value proposition can help companies keep current employees and attract new ones.
Here’s what to keep in mind when developing and commercializing software as a medical device.
A global leader in prostheses, Ottobock set out to also become the ESG leader in its field. The key: measuring the socioeconomic benefit of its products.
A sea change is underway in how companies win regulatory approval for new health care products—particularly in the use of digital technology—and which markets they prioritize.
A next-generation commercial model is needed fast. Those who adopt it quickly will be rewarded handsomely.
COVID-19 offered valuable lessons in combating epidemic-level disease. Four measures can help institutionalize what we’ve learned.
BCG Executive Perspectives offer insights on global topics that matter most to leaders in the public and private sectors. Explore these topics and read the latest thinking from BCG's experts below.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?
BCG Managing Director & Partner Johanna Benesty looks at barriers to "equitable access"—making sure COVID-19 therapeutics are available to all—while sharing a creative approach to vaccine research and development.
